Skip to main content

Preventing Symptom Escalation Among Mild COVID-19 Patients

05/05/2021

With several treatments now available to care for the most urgent and severe cases of COVID-19, researchers are setting their sights on a potential intervention for the early stages of the virus. 

Vancouver Coastal Health Research Institute (VCHRI) clinician-scientist Dr. Sara Belga is investigating whether ciclesonide, a common anti-inflammatory drug, could help speed up recovery, and put a stop to disease progression and potential hospitalization among patients with mild COVID-19. 

“The COVID-19 virus affects a person's airways where it replicates and can eventually cause breathing difficulties and lung damage," says Belga, who is the principal investigator in British Columbia of the CONTAIN study. “Ciclesonide has been shown to prevent viral activity against SARS-CoV-2 in some lab-based studies; and, we hypothesize that giving it to patients early in the course of the disease could prevent the virus from replicating further and causing an increased inflammatory response."  

The study is recruiting individuals living in Quebec, Ontario or British Columbia. Adults 18 years of age and older can qualify to participate if they apply via the CONTAIN study's online portal within five days of being diagnosed with COVID-19. Eligible participants must also be recovering at home with a mild fever, shortness of breath and/or symptomatic cough. 

Close to equal halves of the anticipated 350 participants of the double-blind randomized controlled clinical trial will receive a saline solution placebo or ciclesonide—which will be mailed to their homes—to self-administer twice daily. 

Participants are then required to fill out online surveys about their symptoms and condition on days one, three, five, seven and 10, as well as on the last day of the 14-day treatment course. 

“We will be checking to see if symptoms have improved within seven days, and if there was an overall symptom improvement and a lack of hospitalization and mortality within the two weeks."

The CONTAIN study team selected ciclesonide as a possible treatment option because of its low rate of side effects and drug interactions, as well as evidence linking this particular steroid with antiviral effects. When inhaled, the medication is directed to areas of the body most affected by the COVID-19 virus, i.e., the nose and airways. 

“Up to now, most COVID-19 research has focused on in-patients with more severe symptoms, including patients in the intensive care unit and those who need oxygen," notes Belga. “There is not as much data about treatments for out-patients who are in the beginning stages of the disease."

“What if this drug, which is relatively inexpensive, could speed up recovery and reduce the severity of the disease? In that case, ciclesonide could become part of the standard of care for early-stage COVID-19 patients. Although this is our hope, we can only answer this question if enough people with COVID-19 enroll in the CONTAIN study."

Read more on vchri.ca and visit the CONTAIN website for more information about the study and how to participate.


Visit the VCH Research Institute website


Visit the Contain COVID-19 website





SOURCE: Preventing Symptom Escalation Among Mild COVID-19 Patients ( )
Page printed:

Copyright © Vancouver Coastal Health. All Rights Reserved.